Phase 3 Boosting Study for the SARS-CoV-2 rS Vaccine
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, observer blinded study to evaluate the safety and
immunogenicity of 2 booster doses of the Omicron variant severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccine adjuvanted
with Matrix-M™ adjuvant (NVX-CoV2515) in previously vaccinated adults. In total, the study
will enroll approximately 980 participants, ≥18 and ≤ 64 years of age. Approximately 490
participants will receive study vaccine for the Omicron variant (NVX-CoV2515) and 490
participants will receive study vaccine for the prototype Wuhan strain (NVX-CoV2373).